Intermountain Healthcare asks for consumers' genetic data to build global DNA database

Intermountain Healthcare is asking adults who have purchased direct-to-consumer DNA tests like AncestryDNA, MyHeritage or 23andMe to upload their genetic results data or genotypes to build a global DNA registry.

Researchers developing the global DNA registry, called the GeneRosity Registry, hope the genetic data could be used in future studies to determine which patients are at risk for developing genetic health problems.

“Our project is creating a resource for future studies,” said Stacey Knight, PhD, MStat, a cardiovascular and genetic epidemiologist at the Intermountain Medical Center Heart Institute. “A person’s DNA is made up of more than three billion individual pairs of genetic codes but finding specific genes that contribute to health problems isn’t easy. That’s why we’re asking people to submit their DNA results, along with as much personal and family medical history as they know.”

Intermountain hopes to reach those who have previously purchased genetic tests to gain data on genes, environment and lifestyle.

“A family medical history can identify people with a higher-than-usual chance of having common disorders such as heart disease, high blood pressure, stroke, certain cancers and diabetes,” Knight said. “These complex disorders are influenced by a combination of genetic factors, environmental conditions, and lifestyle choices. We’ll be able to use the information people submit to validate new genetic and disease findings, discover new genetic mutation and genetic profiles, and drive future studies. If the GeneRosity Registry’s researchers are successful in future research using these data, others will benefit greatly.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

After their proposal for a new American Board of Cardiovascular Medicine was shot down earlier this year, cardiology groups have asked the AMA for some support. "We feel like it's time for us to blaze our own path," one specialist explained. 

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.